Cancer Immunoprevention Network

The Cancer Immunoprevention Network (CIP-Net), established by the National Cancer Institute (NCI), advances the understanding of fundamental immunoprevention mechanisms, drives the discovery of novel strategies, and supports the preclinical development and testing of new interventions. More info: nci-cipnet.org

🧬CIP-Net Project Spotlight: What drives the transition from MGUS to multiple myeloma? This project led by Drs. Madhav Dhodapkar @fredhutch , Richard Flavell, & Noah Palm @Yale explores how gut microbes may act as antigenic triggers for B cells, combining microbiome profiling, humanized models, and clinical studies to uncover new paths for prevention and intervention. Learn more: nci-cipnet.org/en/members/ug3…

Register now for the @theNCI Division of Cancer Prevention Early Career Scientist Spotlight Research Seminar Series. events.cancer.gov/dcp/early-care… The upcoming featured talks: Dr. Tengteng Wang @TengtengW_EPI, on Microbes, Hormones, and Diet: Translating Microbiome Science into Breast Cancer Prevention and Control; and Dr. Abel Martel Martel on Decoding the Immune Landscape of Mismatch Repair–Deficient Colorectal Carcinogenesis.

Restricting lipid accumulation in tumor-infiltrating neutrophils mediates caloric restriction-induced anti-cancer effects dlvr.it/TRGyHq

🧬CIP-Net Project Spotlight: Smoldering multiple myeloma (SMM) is a premalignant plasma cell disorder with variable risk of progression to symptomatic multiple myeloma. While high-risk patients may enter treatment trials, most low to intermediate risk individuals lack recommended interventions. Led by Drs. Peter Leif Bergsagel @Leif_Bergsagel and Marta Chesi @marta_chesi of @MayoClinic , this project investigates how inflammatory cues within the bone marrow microenvironment promote malignant progression during SMM. Learn more👉nci-cipnet.org/en/members/ug3…

New #JITC commentary: Engineering macrophages for effective and safe targeting of CD47 cancer cells in the tumor microenvironment jitc.bmj.com/content/14/2/e… @fertorresandon

Decidual immune activation by extravillous trophoblasts drives maternal-fetal tolerance and immunity dlvr.it/TRDxjV #immunology

Online Now: Macrophages: Targets for next-generation cancer immunotherapy dlvr.it/TRB5tg

📣Faculty recruitment - cancer interception researcher @FoxChaseCancer. See JD 👇

In the latest issue! Sensory neurons drive immune exclusion by stimulating a dense extracellular matrix in the breast cancer tumor microenvironment dlvr.it/TR752Q

In our latest, we used single cell ATAC to take a deep dive into kidney cancer chromatin programs and their relation to mutations in epigenetic regulators + interferon + endogenous retroviruses - congrats Sabrina Camp, Kevin Bi et al!

Only a few spots remaining! This is a great opportunity for early stage investigators to showcase their work to a broad scientific community. 2026 Annual Call for Nominations to Highlight Early Career Scientists Conducting Research within the Mission of the @theNCI Division of Cancer Prevention. Don’t miss the chance to nominate or apply! prevention.cancer.gov/funding-and-gr…

At today’s #CIPNetSCMeeting, Drs. Haval Shirwan and Preethi Gunaratne announced the formation of a White Paper Task Force and invited additional interested participants to join. Dr. Alan Hutson @Amherst73 shared DRCC updates. Drs. Leif Bergsagel @Leif_Bergsagel and Marta Chesi presented progress on their UG3 project - Preclinical Studies for the Immunoprevention of Multiple Myeloma. We also welcomed our new Associate Member, Dr. Dinler Amaral Antunes!

🧬CIP-Net Project Spotlight: Immune determinants modulating cancer development in #LynchSyndrome Led by Drs. @NinaBhardwaj , Aimee Lucas & Robert Samstein of @IcahnMountSinai, this project will define the shared frameshift neoantigens and T cell features that restrain progression from precancerous polyps to CRC and reveal new opportunities for #Immunoprevention. Learn more👉nci-cipnet.org/en/members/ug3…